. In the United States, the average annual increase in thyroid cancer incidence of 6.6% between 2000 and 2009 is the highest among all cancers 2 . Although the death rate of thyroid cancer is relatively low, the rate of disease recurrence or persistence is high, which is associated with increased incurability and patient morbidity and mortality 3 . There are several histological types and subtypes of thyroid cancer with different cellular origins, characteristics and prognoses 4 (TABLE 1) . There are two types of endocrine thyroid cells -follicular thyroid cells and parafollicular C cells -from which thyroid cancers are derived. Follicular thyroid cell-derived tumours, including papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), account for the majority of thyroid malignancies. PTC and FTC are collectively classified as differentiated thyroid cancer (DTC). Parafollicular C cell-derived medullary thyroid cancer (MTC) accounts for a small proportion of thyroid malignancies 2 . The primary molecular mechanism underlying MTC tumorigenesis is the aberrant activation of RET signalling (which is caused by RET mutations 5 ), which are not present in follicular thyroid cell-derived tumours. The molecular pathogenesis of follicular thyroid cell-derived tumours is the focus of this Review.
Conventional surgical thyroidectomy with adjuvant ablation by radioiodine treatment has been the mainstay of treatment for follicular thyroid cell-derived cancer, but it is often not curative. The recent progress in understanding the molecular pathogenesis of thyroid cancer has shown great promise for the development of moreeffective treatment strategies for thyroid cancer. This has mainly resulted from the identification of molecular alterations, including the genetic and epigenetic alterations of signalling pathways -such as the RAS-RAF-MEK-MAPK-ERK pathway (MAPK pathway) and the PI3K-AKT pathway -which is reshaping thyroid cancer medicine. This Review discusses the recent remarkable progress in understanding the molecular pathogenesis and mechanisms of thyroid cancer.
Common genetic alterations in thyroid cancer
Gene mutations. Numerous genetic alterations that have a fundamental role in the tumorigenesis of various thyroid tumours have been identified (TABLE 2) . A prominent example is the T1799A transverse point mutation of BRAF, which results in the expression of BRAF-V600E mutant protein and causes constitutive activation of this serine/threonine kinase [6] [7] [8] [9] [10] [11] . BRAF V600E mutation occurs in approximately 45% of PTCs 12 . There are also a few rare types of BRAF mutations identified in PTC, which mostly affect nucleotides around codon 600 and constitutively activate the BRAF kinase 13, 14 . The requirement for BRAF-V600E to maintain tumour growth was initially demonstrated in a xenograft tumour model 15 . A previous comprehensive multicentre study demonstrated a strong association of BRAF V600E with poor clinicopathological outcomes of PTC, including aggressive pathological features, increased recurrence, loss of radioiodine avidity and treatment failures 16 . This was
Differentiated thyroid cancer
(DTC). Collectively includes both papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), which are histologically differentiated, by comparison with poorly differentiated thyroid cancer (PDTC) and undifferentiated anaplastic thyroid cancer (ATC).
Radioiodine treatment
A classical treatment for patients with thyroid cancer. It is used after total thyroidectomy and consists of treating patients with the radioiodine isotope 131 I, which emits high-energy β-particles and takes advantage of the unique function of thyroid follicular cells to accumulate iodide as a substrate for the synthesis of thyroid hormone.
Molecular pathogenesis and mechanisms of thyroid cancer
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Abstract | Thyroid cancer is a common endocrine malignancy. There has been exciting progress in understanding its molecular pathogenesis in recent years, as best exemplified by the elucidation of the fundamental role of several major signalling pathways and related molecular derangements. Central to these mechanisms are the genetic and epigenetic alterations in these pathways, such as mutation, gene copy-number gain and aberrant gene methylation. Many of these molecular alterations represent novel diagnostic and prognostic molecular markers and therapeutic targets for thyroid cancer, which provide unprecedented opportunities for further research and clinical development of novel treatment strategies for this cancer.
MAPK pathway
This pathway has a fundamental role in the regulation of cell growth, proliferation, apoptosis and metabolic activities, through regulating the expression of various genes.
PI3K-AKT pathway
This pathway also has a fundamental role in the regulation of cell growth, proliferation, apoptosis and metabolic activities, through regulating the expression of various genes.
Pten
A tumour suppressor gene, the protein product of which converts phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to phosphatidylinositol (4,5)-trisphosphate (PIP2), counteracting the conversion of PIP2 to PIP3 by PI3K and thus terminating PI3K-AKT signalling.
Cowden's syndrome
Also known as Cowden's disease or multiple hamartoma syndrome. A rare, autosomally inherited disorder that is caused by mutations or defects in the tumour suppressor gene PTEN and is characterized by multiple tumour-like growths called hamartomas and an increased risk of certain cancers, such as breast cancer and follicular thyroid cancer.
subsequently confirmed in numerous other studies, although, perhaps owing to variations in study design, some studies showed inconsistent results, as summarized and discussed in large meta-analyses that uniformly support the aggressive role of BRAF V600E mutation in PTC 17, 18 . BRAF V600E -transgenic mice also developed aggressive PTC [19] [20] [21] . Interestingly, some human PTC tumours have recently been found to exhibit intratumour heterogeneity in the BRAF genotype -with a minority of cells harbouring BRAF V600E and the majority harbouring wild-type BRAF 22 . This raises an interesting 'chicken and egg' puzzle of whether BRAF-V600E initiates PTC tumorigenesis or instead BRAF V600E occurs following the development of a thyroid tumour 23 . Although it is possible that BRAF V600E could be a secondary genetic event in PTC tumorigenesis as previously proposed 24 , an alternative possibility is that once PTC is initiated by BRAF V600E , secondary oncogenic alterations could take over to drive the tumorigenesis of PTC such that BRAF mutation is no longer selected for 23 . Second in prevalence to BRAF mutations in thyroid cancer are RAS mutations. RAS is in its active state when bound with GTP. The intrinsic GTPase of RAS hydrolyses GTP and converts RAS into an inactive GDPbound state, thus terminating RAS signalling. RAS mutations cause the loss of its GTPase activity, thus locking RAS in a constitutively active GTP-bound state. There are three isoforms of RAS: HRAS, KRAS and NRAS, and NRAS is predominantly mutated in thyroid tumours, mostly involving codons 12 and 61. Although RAS is a classical dual activator of the MAPK and PI3K-AKT pathways, RAS mutations seem to preferentially activate the PI3K-AKT pathway in thyroid tumorigenesis, as suggested by the preferential association of RAS mutations with AKT phosphorylation in thyroid cancers 25, 26 .
The common occurrence of RAS mutations in follicular thyroid adenoma (FTA), a presumed premalignant lesion, suggests that activated RAS may have a role in early follicular thyroid cell tumorigenesis. However, additional genetic alterations other than RAS mutation are apparently required to transform FTA into thyroid cancer. This is consistent with studies in which the expression of mutant HRAS was induced in normal thyroid cells in vitro, which resulted in only welldemarcated and differentiated colonies with phenotypes consistent with FTA 27 and cell proliferation with normal differentiation 28 , activating PIK3CA mutations in thyroid cancer occur in exon 9 and exon 20. AKT1 mutations were found in metastatic thyroid cancers in one study, and their functional relevance remains to be established 35 .
Other important genes that are mutated in thyroid tumorigenesis include β-catenin (CTNNB1) 37, 38 , TP53 39, 40 , isocitrate dehydrogenase 1 (IDH1) 41, 42 , anaplastic lymphoma kinase (ALK) 43 and epidermal growth factor receptor (EGFR) 44 . The preferential occurrence of these mutations in PDTC and ATC, which are the most aggressive thyroid cancers, suggests that they may have a role in the progression and aggressiveness of thyroid cancer. In Hürthle-cell thyroid carcinoma (HCTC), mutations of NADH dehydrogenase (ubiquinone) 1α subcomplex 13 (NDUFA13; also known as GRIM19) are fairly common 45 . Unlike other types of thyroid cancers, HCTC does not harbour classical genetic alterations, such as BRAF and RAS mutations or RET-PTC 46, 47 , but commonly harbours DNA haploidization in recurrent disease 47 .
Gene amplifications and copy-number gains. Oncogenic gene amplification or copy-number gain are additional prominent genetic mechanisms in thyroid tumorigenesis (TABLE 3) . This is particularly the case for genes encoding receptor tyrosine kinases (RTKs) 26 . Copynumber gains are also common for the genes encoding PI3K-AKT pathway members, including PIK3CA, PIK3CB, 3-phosphoinositide-dependent protein kinase 1 (PDPK1; also known as PDK1), AKT1 and AKT2 (REFS 25, 26, 32) . Overall, genetic copy-number gains of these genes are more prevalent in ATC than in DTC, suggesting that these genetic alterations are important for the progression and aggressiveness of thyroid cancer. Copy-number gain of these genes in ATC could occur either through genetic amplification or chromosomal instability and aneuploidy. An important and
At a glance
• Thyroid cancer is a common endocrine malignancy, and exciting progress has occurred in recent years in understanding its molecular pathogenesis.
• Genetic and epigenetic alterations are the driving forces of thyroid cancer.
Examples of these alterations include mutations in BRAF (BRAF   V600E   ) , RAS, PIK3CA, PTEN, TP53, β-catenin (CTNNB1), anaplastic lymphoma kinase (ALK) and isocitrate dehydrogenase 1 (IDH1), translocations (RET-PTC and paired box 8 (PAX8)-peroxisome proliferator-activated receptor-γ (PPARG)) and aberrant gene methylation.
• At the core of the molecular pathogenesis of thyroid cancer is the uncontrolled activity of various signalling pathways, including the MAPK, PI3K-AKT, nuclear factor-κB (NF-κB), RASSF1-mammalian STE20-like protein kinase 1 (MST1)-forkhead box O3 (FOXO3), WNT-β-catenin, hypoxia-inducible factor 1α (HIF1α) and thyroid-stimulating hormone (TSH)-TSH receptor (TSHR) pathways.
• The progression of thyroid cancer is a process of accumulation of genetic and epigenetic alterations with corresponding progressive derangements of signalling pathways. These are accompanied by numerous secondary molecular alterations, both in the cell and in the tumour microenvironment, which, acting in cooperation, amplify and synergize their impacts on thyroid tumorigenesis.
• Aberrant silencing of thyroid iodide-handling genes and consequent loss of radioiodine avidity of thyroid cancer promoted by BRAF-V600E is a unique molecular pathological process in thyroid cancer, which causes the failure of radioiodine treatment.
• The recent molecular findings provide unprecedented opportunities for further research and clinical development of novel molecular-based treatment strategies for thyroid cancer.
Copy-number gain
A genetic abnormality in which the copy number of a chromosomal region or gene is more than the normal two copies (one paternal allele and one maternal allele), which occurs through the amplification of a local region of DNA within a chromosome, or through aneuploidy, in which multiple copies or fragments of identical chromosomes are present.
expected consequence of these copy-number gains is the activation of downstream signalling pathways, as is suggested by the association of copy-number gains of genes encoding RTKs with increased phosphorylation of AKT and ERK in thyroid cancer 26 . Many of the genes with copy-number gains are proto-oncogenes. A mechanism for them to contribute to thyroid tumorigenesis is through increased protein expression and consequent aberrant activation of the signalling pathways in which they are involved 25, 26, 33 . It is interesting to note that in DTCs, PIK3CA mutation is mutually exclusive with PIK3CA copy-number gain 31, 33 , suggesting that either of these genetic alterations is sufficient to promote thyroid tumorigenesis through the PI3K-AKT pathway. However in aggressive undifferentiated ATC, PIK3CA mutations and amplifications often occur simultaneously in the same tumour 26, 33 , which is a mechanism through which mutant PIK3CA can be amplified to drive the progression and aggressiveness of thyroid cancer.
Gene amplification or copy-number gain of the IQ-motif-containing GTPase-activating protein 1 (IQGAP1) is another important genetic event that has been recently discovered in thyroid cancer 48 . IQGAP1 is a multifunctional scaffold protein that has an important role in human tumorigenesis 49 . IQGAP1 amplification was found to increase protein expression and to be associated with invasiveness of thyroid cancer cells. Interestingly, coexistence of IQGAP1 copy-number gain and BRAF V600E mutation was particularly associated with a high incidence of recurrent PTC 48 .
Gene translocations.
Gene translocation resulting in oncogenic rearrangements in thyroid cancer is best exemplified by RET-PTC. There are more than 10 types of RET-PTC translocation, as determined by the types of partner genes, and the most common types are RET-PTC1 and RET-PTC3 [50] [51] [52] . RET is a proto-oncogene encoding an RTK. RET-PTC occurs as a consequence of genetic recombination between the 3′ tyrosine kinase portion of RET and the 5′ portion of a partner gene, such as the coiled-coil domain-containing gene 6 (CCDC6; also known as H4) in RET-PTC1 and nuclear receptor co-activator 4 (NCOA4; also known as ELE1) in RET-PTC3 (REFS 53, 54) . Spatial contiguity of RET and the partner gene in the nucleus is a structural basis for the formation of RET-PTC rearrangements 55 . The rearrangements result in ligand-independent dimerization and constitutive tyrosine kinase activity of RET. RET-PTC can occur in benign FTA and follicular variant PTC (FVPTC), but more commonly in classical PTC 56 . A recent study found a correlation between the presence of RET-PTC and a high growth rate of benign thyroid tumours 57 . However, the role of RET-PTC in early thyroid tumorigenesis is unclear. RET-PTC is a classical oncoprotein that activates the MAPK and PI3K-AKT pathways 58, 59 . RET-PTC activates both pathways by recruiting signalling adaptors to phosphorylated Tyr1062 on the intracellular domain of the RET fusion protein 60 . It is thus not surprising that RET-PTC occurs 
Follicular thyroid tumours
Collectively includes follicular thyroid adenoma (FTA), follicular thyroid cancer (FTC) and follicular variant papillary thyroid cancer (FVPTC); they share common dense follicular cell architectures.
Gene methylation
An epigenetic covalent addition of a methyl group to the fifth carbon of the cytosine residue in a CpG dinucleotide, typically in CpG islands (that is, CpG-rich regions) in the 5ʹ-flanking promoter regions of genes. Such methylation is usually closely associated with chromatin remodelling and silencing of the corresponding genes.
in FTA and FVPTC; these are follicular thyroid tumours in which the PI3K-AKT pathway has a primary role in tumorigenesis 61 . The paired box 8 (PAX8)-peroxisome proliferatoractivated receptor-γ (PPARG) fusion gene (PAX8-PPARG) is another prominent recombinant oncogene in thyroid cancer, occurring in up to 60% of FTC and FVPTC [62] [63] [64] . PAX8-PPARG also occurs in FTA 64 , although, like RET-PTC, its prevalence is low in benign thyroid tumours and its oncogenic role is unclear. PAX8-PPARγ exerts a dominant-negative effect on the wild-type tumour suppressor PPARγ and also transactivates certain PAX8-responsive genes 65 . Interestingly, the expression of PPARγ was dramatically reduced in FTC that developed in the TRβPV mouse model -which expresses a knock-in dominant-negative mutant of human thyroid hormone receptor-β (TRβ) -resulting in follicular thyroid tumorigenesis 66 . An AKAP9-BRAF fusion gene resulting in activation of the BRAF kinase also occurs in ionizing-radiation-induced PTC 67 , but not in sporadic PTC 68 . Unlike RET-PTC, the importance of AKAP9-BRAF in thyroid tumorigenesis is probably limited owing to its rarity.
Aberrant gene methylation.
Aberrant gene methylation is an epigenetic hallmark of human cancer -which is also common in thyroid cancer 69 -that usually silences a gene when occurring in the promoter regions. BRAF V600E mutation was found to be associated with hypermethylation of several tumour suppressor genes, including tissue inhibitor of metalloproteinases 3 (TIMP3), SLC5A8, death-associated protein kinase 1 (DAPK1) and retinoic acid receptor-β (RARB) 70 . A recent DNA methylation microarray study revealed broad hypermethylation of genes throughout the genome driven by BRAF-V600E signalling in PTC cells 71 . Interestingly, this study also revealed a large range of genes throughout the genome that, driven by BRAF-V600E, became hypomethylated and hence overexpressed. These hypermethylated or hypomethylated genes have important established metabolic and cellular functions. Thus, alterations in gene methylation coupled to BRAF-V600E and probably to other oncoproteins represent a prominent epigenetic mechanism in thyroid tumorigenesis.
Promoter methylation of PTEN is also common in FTC and ATC [72] [73] [74] , which is consistent with the loss of expression of PTEN that is found in a subset of these thyroid cancers 73, 75, 76 . PTEN methylation is associated with genetic alterations of the PI3K-AKT pathway in thyroid tumours, including mutations of various isoforms of RAS, PIK3CA mutation and amplification, and PTEN mutations 72 . This is consistent with a model in which aberrant activation of the PI3K-AKT pathway, driven by activating genetic alterations, causes aberrant methylation and hence silencing of PTEN, which in turn leads to failure to terminate the PI3K-AKT signalling and creates a self-amplifying loop 72 . Despite the identification of these common genetic alterations in thyroid cancers, it is important to note that approximately 30-35% of DTCs do not harbour known genetic alterations, and so further investigation is required to identify the underlying genetic backgrounds.
Altered signalling pathways in thyroid cancer
The MAPK signalling pathway. The MAPK pathway has a fundamental role in the regulation of cell proliferation and survival and in human tumorigenesis (FIG. 1) . The importance of this pathway has been well established in thyroid tumorigenesis, particularly for PTC 77, 78 . In thyroid cancer, the MAPK pathway is driven by activating mutations, including BRAF and RAS mutations, by RET-PTC and, in some cases, by the recently discovered ALK mutations 43 . MAPK-mediated thyroid tumorigenesis involves a wide range of secondary molecular alterations that synergize and amplify the oncogenic activity of this pathway, such as genome-wide hypermethylation and hypomethylation 71 . Additionally, upregulation of various , hypoxia-inducible factor 1α (HIF1α) 88 , prokineticin 1 (PROK1; also known as EG-VEGF) 89 , urokinase plasminogen activator (uPA) and its receptor (uPAR) 90, 91 , transforming growth factor-β1 (TGFβ1) [92] [93] [94] Figure 1 | The MAPK and related pathways in thyroid cancer. Shown in the middle of the figure is the classical MAPK pathway leading from an extracellular mitogenic stimulus that activates a receptor tyrosine kinase (RTK) in the cell membrane, to RAS, RAF (shown as BRAF-V600E), MEK and ERK. ERK is activated by phosphorylation (P) and enters the nucleus where it upregulates tumour-promoting genes and downregulates tumour suppressor genes and thyroid iodide-handling genes. On the left side of the figure is the nuclear factor-κB (NF-κB) pathway, in which extracellular stimuli activate the pathway by acting on receptors in the cell membrane, leading to activation of the inhibitor of κB (IκB) kinase (IKK), resulting in the phosphorylation of IκB. Phosphorylated IκB becomes dissociated from NF-κB, which is normally bound with IκB in a complex and sequestered in the cytoplasm. Phosphorylated IκB undergoes ubiquitylation and proteasomal degradation. Free NF-κB then enters the nucleus to promote the expression of tumour-promoting genes. Through an undefined mechanism that is independent of MEK signalling, BRAF-V600E promotes the phosphorylation of IκB and the release of NF-κB, thus activating the NF-κB pathway. Shown on the right side of the figure is the RASSF1-mammalian STE20-like protein kinase 1 (MST1)-forkhead box O3 (FOXO3) pathway. Activated by extracellular pro-apoptotic stimuli through membrane receptors, RASSF1A activates MST1. Activated MST1 then phosphorylates FOXO3 on Ser207. The resulting phosphorylated FOXO3 becomes dissociated from 14-3-3 proteins in the cytoplasm. 14-3-3 proteins undergo proteasomal degradation, and phosphorylated FOXO3 enters the nucleus to promote the expression of pro-apoptotic genes in the FOXO pathway. BRAF-V600E directly interacts with and inhibits MST1 and prevents its activation by RASSF1A, thereby suppressing the pro-apoptotic signalling of the FOXO3 pathway. The downward arrow for the FOXO activities shown in the nucleus indicates this negative effect of BRAF-V600E on pro-apoptotic genes, which are normally upregulated by the RASSF1A-MST1-FOXO3 pathway. The triple independent coupling of BRAF-V600E to the pathways shown here represents a unique and powerful mechanism of thyroid tumorigenesis driven by BRAF-V600E. DAPK1, death-associated protein kinase 1; HIF1A, hypoxia-inducible factor 1α; MMP, matrix metalloproteinase; NIS, sodium-iodide symporter; TGFB1, transforming growth factor β1; TIMP3, tissue inhibitor of metalloproteinases 3; TPO, thyroid peroxidase; TSHR, thyroid-stimulating hormone receptor; TSP1, thrombospondin 1; UPA, urokinase plasminogen activator; UPAR, urokinase plasminogen activator receptor; VEGFA, vascular endothelial growth factor A.
Capsular invasiveness
A phenomenon in which thyroid cancer invades the connective tissue capsule that surrounds the tumour, which is a defining feature of progression to malignancy from a benign thyroid tumour.
and thrombospondin 1 (TSP1) 93 . These proteins are all established players in human tumorigenesis through a variety of mechanisms that drive cancer cell proliferation, growth, migration and survival, as well as tumour angiogenesis, invasion and metastasis.
Many of these proteins are key constituents of the unique extracellular matrix (ECM) microenvironments that have been proposed to be important in the pathogenesis of thyroid cancer driven by oncoproteins such as BRAF-V600E
95
. It is now clear that the ECM microenvironment does not only function as a structural support for the cellular elements of cancer, but it also has a profound impact on the behaviours of cancer cells, including their viability, proliferation, adhesion and motility. Thyroid cancer cells and stromal cells, such as fibroblasts and macrophages, produce proteins that form paracrine and autocrine signalling loops. For example, BRAF-V600E-mediated MAPK pathway activation promotes the release of TSP1 into the ECM where it interacts with and modulates other proteins. These include integrins and non-integrin cell-membrane receptors, matrix proteins, cytokines, VEGFA and MMPs, which in turn activate signalling in thyroid cancer cells and promote tumour progression and metastasis 93, 95 . Another example is the tumour-promoting cytokine TGFβ1, which is released into the ECM owing to the activation of the BRAF-V600E-MAPK pathway 92, 94 . Cytokines can create an inflammatory microenvironment that may produce reactive oxygen species and oxidative stress, which may in turn stimulate the MAPK pathway and augment thyroid tumorigenesis 96 . Thus, secondary molecular alterations in the tumour ECM microenvironment, triggered by the aberrant signalling of the MAPK pathway, have an important role in the pathogenesis of thyroid cancer.
In terms of stromal cells in the tumour microenvironment, an important role of tumour-associated macrophages is that they produce cytokines such as TGFβ1. The role of stromal fibroblasts in thyroid tumorigenesis seems to be affected by the expression patterns of the two fibroblast growth factor receptor 2 (FGFR2) isoforms, FGFR2-IIIb and FGFR2-IIIc, in cancer cells and fibroblasts: co-implantation of thyroid cancer cells and fibroblasts expressing the same type of FGFR2 isoform did not affect xenograft tumour progression, whereas co-implantation of thyroid cancer cells and fibroblasts that respectively expressed FGFR2-IIIb and FGFR2-IIIc resulted in increased tumour progression 97 . These results highlight the importance and complexity of cellular and molecular constituents in determining the impact of the microenvironment on thyroid cancer cell behaviour.
The PI3K-AKT signalling pathway. The PI3K-AKT pathway also has a fundamental role in thyroid tumorigenesis 61, 98 (FIG. 2) . Early evidence to support the role of this pathway in thyroid tumorigenesis came from the finding that Cowden's syndrome (which is caused by germline mutations of PTEN) was associated with FTA and FTC
99
. A functional role for the PI3K-AKT pathway in sporadic thyroid tumorigenesis was initially revealed by the finding of increased expression and activation of AKT in thyroid cancers, particularly FTC [100] [101] [102] . Among the three AKT isoforms, AKT1 and AKT2, but not AKT3, were found to be robustly expressed and activated in thyroid cancer, suggesting a particularly important role for these two isoforms in thyroid tumorigenesis 101 . In the TRβPV transgenic mouse model -in which the PI3K-AKT pathway is activated, which involves the interaction of TRβPV with the p85α regulatory subunit of PI3K -FTC spontaneously developed 103, 104 , and the activation and nuclear localization of AKT1 was observed 105 . Human tumour studies suggested that the invasiveness and metastasis of FTC promoted by the PI3K-AKT pathway particularly involved the activation and nuclear localization of AKT1 (REF. 102 ). This is consistent with the occurrence of AKT1 mutations in metastatic thyroid cancers 35 . Furthermore, Akt1 ablation delayed or prevented tumour progression, vascular intravasation and distant metastasis of FTC in TRβPV mice 106 . The role of AKT2 in thyroid tumorigenesis has also been demonstrated in vivo, as the occurrence of thyroid tumours was reduced in Pten
. Thus, whereas the MAPK pathway has a central role primarily in PTC, the PI3K-AKT pathway has such a role primarily in FTC and its invasion and metastasis. This is consistent with genetic alterations in the PI3K-AKT pathway occurring most frequently in FTC, whereas those in the MAPK pathway occur most frequently in PTC Increased NF-κB activation in thyroid cancer cell lines and tissues has long been documented [116] [117] [118] . Recent studies demonstrate that the NF-κB pathway controls proliferative and anti-apoptotic signalling pathways in thyroid cancer cells 119, 120 . The NF-κB pathway is involved in upregulating the expression of several oncogenic proteins that are also upregulated by the MAPK pathway. Furthermore, RET-PTC, RAS and BRAF-V600E -members of the MAPK pathway -can cause activation of the NF-κB pathway in thyroid cancers 119 . Interestingly, NF-κB signalling was upregulated by expression of BRAF-V600E 121, 122 , but not by expression Nature Reviews | Cancer 
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of a constitutively active mutant of MEK in NIH3T3 cells 123 , suggesting a direct coupling of BRAF-V600E to the NF-κB pathway. Through a mechanism that is not yet specifically defined, BRAF-V600E was shown to cause IκB degradation (and consequent activation of NF-κB) independently of MEK-ERK signalling in thyroid cancer cells 84 . This dual coupling of BRAF-V600E to the NF-κB pathway and to the MEK-ERK pathway is consistent with the finding that simultaneously suppressing the two pathways using NF-κB and MEK inhibitors synergistically inhibited the proliferation of thyroid cancer cells harbouring a BRAF-V600E mutation 124 .
The RASSF1-MST1-FOXO3 signalling pathway. RASSF1 is a member of the RAS association domain family, which, in response to apoptotic signalling, associates with and activates mammalian STE20-like protein kinase 1 (MST1; also known as STK4) 125 . Activated MST1 phosphorylates Ser207 in the forkhead domain of the forkhead transcription factor FOXO3. This phosphorylation disrupts the interaction of FOXO3 with 14-3-3 proteins in the cytoplasm and promotes FOXO3 translocation to the nucleus, where it promotes the transcription of pro-apoptotic genes 126 (FIG. 1) . Thus, this RASSF1-MST1-FOXO3 pathway has an important tumour-suppressive role by promoting apoptosis.
Hypermethylation of the promoter of RASSF1A is common and is associated with its silencing in thyroid cancers 127, 128 . This occurs even in benign FTA, albeit to a lesser extent, suggesting that impairment of the RASSF1-MST1-FOXO3 pathway is involved in early thyroid tumorigenesis 128 . Activation of the RASSF1-MST1-FOXO3 signalling pathway promoted thyroid cancer cell apoptosis 21 . Interestingly, this study demonstrated that BRAF-V600E, but not wild-type BRAF, directly interacted with the carboxyl terminus of MST1 and inhibited its kinase activities, resulting in decreased FOXO3 transactivation. This was independent of MEK-MAPK signalling. This suggests that, in addition to the classical coupling to MEK-MAPK, negative regulation of RASSF1-MST1-FOXO3 is a mechanism that is involved in BRAF-V600E-driven thyroid tumorigenesis. This unique mechanistic model explains the finding that thyroid cancers that developed in BRAF
V600E
Mst1
−/− transgenic mice were more aggressive than those that developed in BRAF V600E mice
21
. The direct interaction of BRAF-V600E with MST1 to prevent RASSF1-mediated MST1 activation also provides an explanation for the mutually exclusive occurrence of BRAF V600E mutation and RASSF1A hypermethylation in thyroid cancer 128 , as either event may be sufficient to inactivate RASSF1-MST1-FOXO3 signalling. Therefore, BRAF-V600E is coupled independently to three major pathways: MEK-MAPK, RASSF1-MST1-FOXO3 and NF-κB, and thus represents a unique and powerful oncogenic mechanism in thyroid tumorigenesis (FIG. 1) . The activation of the PI3K-AKT pathway, such as that induced by PTEN inactivation, can also downregulate the activities of the RASSF1-MST1-FOXO3 pathway in FTC 114 . This involves AKT-mediated phosphorylation of FOXO family members, which causes their translocation . PIP3 activates 3-phosphoinositide-dependent protein kinase 1 (PDK1; also known as PDPK1), which consequently associates with AKT and leads to phosphorylation (P) and activation of AKT by PDK1. Phosphorylated AKT, which is an activated form of AKT, enters the nucleus where it induces tumour-promoting genes. In the cytoplasm, phospho-AKT also activates other signalling molecules or pathways, a prominent one being the mTOR pathway, which has an important role in tumorigenesis by promoting translation. Phospho-AKT can also directly phosphorylate glycogen synthase kinase 3β (GSK3β) and consequently inactivates it. GSK3β normally inhibits β-catenin, thus the effect of phospho-AKT is to relieve GSK3β-mediated suppression of β-catenin. Consequently, β-catenin can enter the nucleus where it promotes the expression of tumour-promoting genes. In the nucleus, phospho-AKT can phosphorylate forkhead box O3 (FOXO3) on its AKT-specific motif. Such phosphorylated FOXO3 is translocated out of the nucleus to the cytoplasm where it binds 14-3-3 proteins to be sequestered in the cytoplasm, thus terminating the pro-apoptotic activities of the FOXO3 pathway. The downward arrow for the FOXO activities in the nucleus in the figure indicates this negative effect of AKT on pro-apoptotic genes in the FOXO pathway, which would otherwise be upregulated by the FOXO3 pathway. This unique coupling of phospho-AKT to the three pathways provides a powerful driving force for thyroid tumorigenesis. The major negative regulatory mechanism of the PI3K-AKT pathway is PTEN, which is a phosphatase that converts PIP3 to PIP2, thus terminating the activation of the pathway. The inset shows the self enhancement mechanism of PI3K-AKT signalling in which genetic-alteration-driven activation of the pathway causes PTEN methylation and silencing with consequent loss of termination of the signalling, thus maintaining the pathway in full and constitutive activation.
from the nucleus to the cytoplasm, where they are sequestered by 14-3-3 proteins, thus reducing the transcription of pro-apoptotic genes 129 (FIG. 2) .
The WNT-β-catenin signalling pathway. The WNT-β-catenin pathway has a well established role in the regulation of cell growth and proliferation, as well as in stem cell differentiation, and its constitutive activation is commonly found in human cancers 130 . β-catenin, when upregulated by upstream WNT signalling, is translocated into the nucleus and transcribes various tumour-promoting genes. In thyroid cancer, activation of WNT-β-catenin signalling is often caused by activating mutations of CTNNB1 (which encodes β-catenin), particularly in PDTC and ATC 37, 38 . Furthermore, the expression of β-catenin was higher in ATC than in DTC 131 . Thus, the WNT-β-catenin pathway seems to have a particularly important role in thyroid tumour aggressiveness.
Aberrant activation of WNT-β-catenin signalling often occurs as a consequence of the activation of the PI3K-AKT pathway in thyroid cancers 132, 133 . This occurs through glycogen synthase kinase 3β (GSK3β), which is directly phosphorylated -and hence inactivated -by AKT 134 . As GSK3β promotes the degradation of β-catenin, its inactivation results in the upregulation of WNT-β-catenin signalling (FIG. 2) . Interestingly, RET-PTC can activate the WNT-β-catenin pathway by activating the PI3K-AKT pathway and also by directly phosphorylating β-catenin in thyroid cancer cells 58 . The HIF1α pathway. It has long been known that hypoxia is a strong stimulus of cancer metabolism, growth and progression. HIF1α is a key mediator of the response to hypoxia, in which it binds to HIF1β (also known as ARNT) to form the HIF1 transcription factor that induces the expression of various genes associated with cell metabolism and tumour angiogenesis 135 . Angiogenesis, which is a key step in the progression of solid tumours, is a common response to intratumoural hypoxia. This process is promoted by VEGFA, the expression of which is strongly upregulated by HIF1. HIF1α is not expressed in normal thyroid tissues but is expressed in thyroid cancers, particularly in aggressive types, such as ATC, and this is consistent with a role in thyroid cancer progression 112, 136 . The oncogene MET, which is another target of HIF1, is also abundantly expressed in association with upregulated HIF1α in thyroid cancer 136 . Interestingly, HIF1 can be upregulated in thyroid cancer by both the PI3K-AKT 112,113 and the MAPK pathways 88 , thus contributing to the effects of these two pathways on thyroid tumour progression.
The thyroid-stimulating hormone receptor signalling pathway. Through activation by thyroid-stimulating hormone (TSH), the TSH receptor (TSHR) has a fundamental role in the regulation of thyroid cell proliferation, differentiation and function, as well as in the development of the thyroid gland 137 . TSHR is a guanine-nucleotidebinding G-protein-coupled receptor that triggers two intracellular signalling pathways: G sα -mediated adenylyl cyclase-cyclic AMP (cAMP) signalling and the G q -or G 11 -mediated phospholipase Cβ-inositol 1,4,5-trisphosphate-intracellular Ca 2+ signalling. FTC spontaneously developed in TRβPV mice, but when these mice were crossed with Tshr −/− mice, no thyroid cancer developed 138 . This study thus elegantly demonstrates the requirement of TSHR signalling in thyroid carcinogenesis in this mouse model. Similar findings were reported in another mouse model in which thyroid-specific knock-in of Braf V600E (LSL-Braf V600E thyroid peroxidase (Tpo)-Cre) caused the development of aggressive PTC, and crossing these mice with Tshr −/− mice resulted in a failure to develop thyroid cancer 139 . In this study, thyroid-specific deletion of Gnas (which encodes G sα ) in LSL-Braf V600E Tpo-Cre mice attenuated thyroid tumour formation. Interestingly, there is a clinical association of higher serum levels of TSH with a higher risk for malignancy of thyroid nodules in humans [140] [141] [142] . However, it is not clear whether TSHR signalling is required directly for the initiation of thyroid cancer or whether it is simply required, as would be expected physiologically, for the TSHR-dependent generation of thyroid cells, from which an oncogene-driven thyroid cancer would originate. Overactivation of TSHR signalling, such as that achieved through activating mutations in TSHR or G sα , is well known to cause benign hyperfunctional FTA 143, 144 . These tumours are almost never malignant, which suggests that TSHR signalling may be protective against malignant transformation of thyroid cells. Consistently, low serum levels of TSH are associated with common genetic variants that predispose to an increased risk of thyroid cancer 145, 146 . It therefore seems that the TSH-TSHR system has a dichotomous role in the development of thyroid cancer: it may suppress malignant transformation of thyroid cells and hence suppress the occurrence of thyroid cancer, but it may promote the growth and progression of thyroid cancer once it has been initiated by oncogenic alterations.
Progressive molecular alterations
Progressive accumulation of genetic alterations. The accumulation of genetic alterations during thyroid tumour progression is probably best exemplified by genetic alterations to members of the PI3K-AKT pathway 61 . Mutations in members of this pathway, including those in RAS (particularly NRAS), PIK3CA and PTEN, as well as PIK3CA amplifications, increasingly occur from FTA to FTC and to ATC 26,31-33, 147 . Hypermethylation of the PTEN promoter also progressively increases in frequency from FTA to FTC and to ATC 72 . The coexistence of these genetic and epigenetic alterations also increasingly occurs from low-grade to high-grade thyroid tumours 31, 33 . Genetic or epigenetic defects of PTEN can occur simultaneously with activating mutations of other genes in the PI3K-AKT pathway; in such cases, the PI3K-AKT pathway can presumably remain maximally activated 26, 33, 72 . Indeed, deletion of Pten accelerated the progression of FTC in TRβPV mice mutation, RAS mutations and RET-PTC in aggressive recurrent PTC and ATC 26, 148, 149 ; these alterations are otherwise mutually exclusive in well-differentiated thyroid cancers 7,9 . It is thus compelling to propose that the process of thyroid cancer progression is one of progressive accumulation of multiple genetic alterations, which synergistically cooperate to amplify their oncogenicity.
Cooperation of the MAPK and PI3K-AKT pathways.
The MAPK and PI3K-AKT pathways are primarily involved in differentiated PTC and FTC, respectively, and the simultaneous activation of both pathways becomes more frequent as the grade of thyroid tumours increases 26, [31] [32] [33] 35 . One study analysed 24 genetic alterations in the major genes of the MAPK and PI3K-AKT pathways in 48 ATC samples and found that the majority (81%) of the samples harboured genetic alterations that could potentially activate both pathways 26 . The coexistence of phosphorylated ERK and AKT was also common in ATC but not in DTC 26 . Thus, genetic alterations that activate the MAPK and PI3K-AKT pathways are an important mechanism that drives the progression of thyroid cancer. In this model, as illustrated in FIG. 3 , when a genetic alteration occurs in the MAPK pathway it drives tumorigenesis of the thyroid cell towards PTC; when a genetic alteration occurs in the PI3K-AKT pathway it drives tumorigenesis towards FTA and FTC. As genetic alterations accumulate and both pathways become activated, the tumour progresses into PDTC and ATC, which is a process that may be further accelerated by additional or secondary genetic alterations, including mutations in TP53, CTNNB1 and ALK. This model is supported by studies of transgenic mice in which the deletion of Pten and knock-in of Kras G12D (to activate both MAPK and PI3K-AKT pathways), but not either genetic manipulation alone, caused the development of aggressive thyroid cancer 29 . Similarly, this phenomenon is observed in melanoma. Transgenic mice with induced expression of BRAF V600E in melanocytes to activate the MAPK pathway alone developed only melanocytic hyperplasias, but the expression of BRAF V600E with Pten deletion (to also activate the PI3K-AKT pathway) caused melanoma with a rapid onset of metastasis 150 . Thus, dual activation of the MAPK and PI3K-AKT pathways may be a common mechanism for promoting tumour progression.
Impairment of the iodide-handling machinery
The main and unique function of follicular thyroid cells is to use iodide to synthesize thyroid hormone 151, 152 (FIG. 4) . In this process, iodide is transported into the cell through the sodium-iodide symporter (NIS) that is located in the basal membrane. At the apical membrane, pendrin transports iodide out of the cell into the lumen of the thyroid follicle. In the lumen of the thyroid follicle, iodide undergoes oxidation by TPO and is incorporated into tyrosine residues of thyroglobulin (TG), which is later cleaved through proteolysis to produce thyroid hormones. This process is upregulated by TSH-mediated activation of TSHR. This is the biological basis for the conventional radioiodine treatment of thyroid cancer, but the iodidehandling machinery is often impaired, particularly in advanced thyroid cancers, thus making radioiodine treatment ineffective.
Aberrant activation of the MAPK pathway has a crucial role in the impairment of the iodide-handling machinery 17 . BRAF V600E mutation is associated with the loss of radioiodine avidity and with radioiodine treatment failure in PTC . A direct role of BRAF V600E in the downregulation of thyroid hormone synthesis pathway genes was demonstrated by showing that induced expression of BRAF-V600E in thyroid cells impaired the expression of almost all of these genes, which was restored by ceasing the expression of BRAF-V600E or by suppressing the MAPK pathway with a MEK inhibitor 161 . Similarly, in thyroid cells expressing RET-PTC1, NIS expression was increased following treatment with a MEK inhibitor 162 . Suppression of BRAF-V600E in mouse models of thyroid cancer also restored the expression of thyroid iodide-handling genes and radioiodine uptake 163 . This aberrant gene silencing by BRAF-V600E may involve alterations to histone acetylation at gene promoters 164, 165 . An autocrine loop involving TGFβ is another mechanism 92 : BRAF-V600E promotes the secretion of TGFβ, which, through the activation of SMADs and consequent impairment of the thyroidgene transcription factor PAX8, is a potent repressor of NIS in thyroid cells 166 . Activation of the PI3K-AKT pathway was also shown to downregulate the iodide-handling machinery in thyroid cells both in vitro and in vivo 167, 168 . Inhibition of the PI3K-AKT pathway induced NIS expression and iodide uptake in human thyroid cancer cells 164, 169 . In addition to NIS, suppression of the PI3K-AKT pathway also induced the expression of TSHR, TPO and TG in human thyroid cancer cells, which was enhanced by treatment with histone deacetylase inhibitors, and radioiodine uptake was correspondingly robustly induced 164 . This could be augmented by co-treatment with TSH 164 . The involvement of both MAPK and PI3K-AKT pathways in the silencing of thyroid iodidehandling genes is consistent with the accumulation of genetic alterations in both pathways as thyroid tumours progress, during which there is an increasing loss of radioiodine avidity.
Translational promises in thyroid cancer
Remarkable advances in the translation of molecular findings in thyroid cancer to the clinic have occurred recently 170 . For example, because of its cancer specificity, the detection of BRAF V600E mutation in fine-needle aspiration biopsy (FNAB) samples was initially tested for the evaluation of thyroid nodules 171, 172 , which has now found increasing clinical use 170, 173 . The diagnostic utility of detecting RET-PTC using FNAB has also been intensively investigated 170 . The combinatorial use of genetic markers identified in FNAB samples, including BRAF mutation, RAS mutations, RET-PTC and PAX8-PPARG, has been shown to improve the diagnostic accuracy for thyroid nodules that are otherwise diagnostically indeterminate by conventional cytology assessment, although this diagnostic approach may need further improvement 174, 175 . Applying genomic information to address clinical issues of thyroid neoplasia has also shown promise. For example, a gene-expression classifier (with high sensitivity and negative predictive power) is being used in the clinic to assist the diagnostic evaluation of indeterminate thyroid nodules 176 . The prognostic application of BRAF V600E mutation has also become part of the clinical management of PTC 170, 173 . A large, multicentre study demonstrated a 
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Cohen, Y. et al. BRAF mutation in papillary thyroid carcinoma. J. Natl Cancer Inst. 95, 625-627 (2003) . This is the first submitted and accepted study that reported a high prevalence of BRAF V600E mutation in thyroid cancer, which was awarded a United States patent.
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Soares 180, 182, 183 and even predicted lymph node metastasis (as determined by prophylactic central neck dissection in patients without preoperative evidence of lymph node metastasis) 183 . It is thus recommended that preoperative testing of BRAF V600E in FNAB samples be used for assisting risk stratification and defining surgical and medical treatments for patients with PTC 170 . Owing to their association with a worse prognosis of PDTC, RAS mutations are also promising prognostic markers for this type of thyroid cancer [184] [185] [186] . It has been recently shown that RAS mutations are also associated with poor clinicopathological outcomes of FTC 187 but this needs to be evaluated further.
Many components of the MAPK and PI3K-AKT pathways, from RTKs in the cell membrane to the various downstream signalling relay molecules, such as BRAF, MEK, AKT and mTOR, are therapeutic targets that are being actively tested for the treatment of thyroid cancer 170 . Novel small-molecule protein-kinase inhibitors have shown promise in clinical trials on thyroid cancer, including axitinib 188 , sorafenib [189] [190] [191] , motesanib 192 and pazopanib 193 . A promising therapeutic strategy is genetic-based targeting of thyroid cancer 194 , as supported by many preclinical studies demonstrating the selective inhibition of BRAF V600E -mutant thyroid cancer cells by various MEK inhibitors 124, [195] [196] [197] [198] [199] and BRAF-V600E-specific inhibitors 200, 201 . The latter include PLX4032 (also known as vemurafenib), which has been recently approved by the US Food and Drug Administration (FDA) for the treatment of BRAF V600E -positive melanoma 202 . Some of these MEK and BRAF-V600E inhibitors are currently being clinically tested for thyroid cancer. Therapeutic targeting of the PI3K-AKT pathway may also be genetically guided, as genetic alterations that activate this pathway confer thyroid cancer cells with remarkably increased sensitivities to AKT and mTOR inhibitors 108, 109 . This therapeutic strategy for thyroid cancer may prove to be useful and should be tested clinically, as encouraged by a recent clinical trial showing that mutations in the PI3K-AKT pathway significantly increased the response rate of breast and gynaecological cancers to inhibitors of the PI3K-AKT pathway 203 . The involvement of multiple signalling pathways in aggressive thyroid cancer suggests that it may be necessary to target them simultaneously for effective treatment. Indeed, single agent clinical trials of various kinase inhibitors in thyroid cancer have generally shown only partial responses. Several recent preclinical studies testing the combination of MEK or BRAF-V600E inhibitors with PI3K, AKT or mTOR inhibitors showed synergistic effects in inhibiting the proliferation and promoting apoptosis of thyroid cancer cells 124, 199, 204, 205 . Synergistic effects of simultaneously targeting the MAPK and PI3K-AKT pathways were even more pronounced in cells that harboured genetic alterations in both pathways 199 . It has been recently demonstrated that simultaneously inhibiting the MAPK, PI3K-AKT and histone deacetylase pathways could more robustly induce the expression of thyroid iodide-handling genes (and thus increase radioiodine uptake) in thyroid cancer cells compared with inhibiting each pathway alone, and this could be enhanced by co-treatment with TSH 164 . Therefore, to restore radioiodine avidity by simultaneously targeting multiple signalling pathways is another promising area of translational research on thyroid cancer.
Concluding remarks
Remarkable progress in understanding the molecular pathogenesis of thyroid cancer has been made in recent years, as exemplified by the elucidation of the fundamental role of signalling pathways, such as the MAPK and PI3K-AKT pathways. Activation of these pathways, often in close connection and cooperation, constitute the primary oncogenic mechanism that promotes the develop ment and progression of thyroid cancer. Central to this mechanism are the many powerful oncogenic alterations that drive these pathways. Important secondary molecular derangements driven by the overactivation of these pathways have also been increasingly uncovered, which synergize and amplify oncogenic signalling in thyroid tumorigenesis. This understanding of the molecular pathogenesis of thyroid cancer has now opened unprecedented opportunities for the development of novel clinical strategies for the management of thyroid cancer. 
